Eton Pharmaceuticals (ETON) Q2 2024 earnings summary

Executive summary

• Achieved record product sales for the 14th consecutive quarter, with Q2 2024 revenue of $9.1 million, up 40% year-over-year, driven by ALKINDI SPRINKLE and Carglumic Acid.

• PKU GOLIKE launched in April 2024, receiving strong market response and increasing patient referrals.

• NDA for ET-400 accepted by FDA with a PDUFA date of February 28, 2025; pre-launch activities underway.

• ET-600 pivotal study to begin in Q3 2024, with NDA submission targeted for early 2025.

• Ended Q2 with $17.7 million in cash and working capital of $7.2 million.

Financial highlights

• Q2 2024 revenue was $9.1 million, up 40% year-over-year, but down from $12.0 million in Q2 2023 due to a $5.5 million royalty sale in the prior year.

• Gross profit for Q2 2024 was $5.6 million, with a gross margin of 62%.

• Net loss was $2.9 million ($0.11 per share), including a $2.0 million one-time NDA fee, compared to net income of $4.6 million ($0.18 per share) in Q2 2023.

• Operating cash flow was $1.3 million in Q2 2024; for the first half of 2024, operating cash flow was $(1.2) million.

• R&D expenses were $3.0 million, up from $1.1 million, mainly due to the NDA filing fee; SG&A expenses were $5.6 million, up from $4.7 million.

Outlook and guidance

• Product sales expected to continue growing quarter-over-quarter for the rest of 2024 and beyond.

• Anticipates reaching positive GAAP net income by year-end, absent unannounced M&A.

• ET-400 commercial launch expected shortly after anticipated FDA approval in early 2025.

• ET-600 pivotal study on track for completion, with NDA submission planned for early 2025 and potential launch in 2026.

• Management expects existing cash and product revenues to fund operations for at least the next twelve months.